US limits use of Johnson & Johnson vaccine over rare blood clots
The US Food and Drug Administration (FDA) has restricted the use of Johnson & Johnson’s COVID vaccine for adults due to the risk of a rare blood clotting syndrome.
The J&J shot is authorised for those aged 18 and above and is one of the three COVID-19 jabs cleared for use in the United States.
The agency said the J&J shot could be administered in cases where authorised or approved vaccines were not accessible or if an individual was less keen on using the other two shots.
The FDA said its analysis had determined that the risk of thrombosis with thrombocytopenia syndrome after the administration of the shot warrants limiting of the authorisation.
J&J has not yet responded to requests for comment.